Improving cardiovascular and renal outcomes in gout: what should we target? (Q38241233)

31 August 2017

Improving cardiovascular and renal outcomes in gout: what should we target? (English)

1 reference

31 August 2017

2

1 reference

31 August 2017

Thomas Bardin

9

0 references

Pascal Richette

Pascal Richette

1

0 references

Leonardo Punzi

Leonardo Punzi

7

0 references

Michael Doherty

Michael Doherty

3

0 references

Eliseo Pascual

Eliseo Pascual

6

0 references

author name string

Tim L Jansen

4

1 reference

31 August 2017

George Nuki

5

1 reference

31 August 2017

Alexander K So

8

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 August 2014

1 reference

Nature Reviews Rheumatology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

11

1 reference

31 August 2017

654-661

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.124

31 August 2017

0 references

cites work

Uric acid and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Definition of hyperuricemia and gouty conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout and coronary heart disease: the Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout and the risk of acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Independent impact of gout on mortality and risk for coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout and the risk for incident heart failure and systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Association between gout and all-cause as well as cardiovascular mortality: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Hyperuricemia and risk of stroke: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Hyperuricemia and incident hypertension: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Mild hyperuricemia induces glomerular hypertension in normal rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Association between serum uric acid and development of type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum uric acid levels and the risk of type 2 diabetes: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Serum uric acid is a determinant of metabolic syndrome in a population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Predictive value of serum uric acid levels for the diagnosis of metabolic syndrome in adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Fructose-rich beverages and risk of gout in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid transport and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid as a target of therapy in CKD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid and chronic kidney disease: which is chasing which?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Cellular characterization of the gouty tophus: a quantitative analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Asymptomatic hyperuricemia: impact of ultrasonography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Allopurinol as a cardiovascular drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Urate in Parkinson's disease: more than a biomarker?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Urate-lowering therapy for gout: focus on febuxostat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Molecular identification of a danger signal that alerts the immune system to dying cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Gout, allopurinol use, and heart failure outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Impact of allopurinol on risk of myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Pharmacotherapy for hyperuricemia in hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of allopurinol on blood pressure: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Uric acid reduction rectifies prehypertension in obese adolescents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Renal function in gout: long-term treatment effects of febuxostat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Hypertension, its treatment, hyperuricaemia and gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Allopurinol treatment and its effect on renal function in gout: a controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Low-dose colchicine for secondary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.124

Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.

31 March 2020

1 reference

12 December 2020

Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals

1 reference

12 December 2020

Effect of insulin on uric acid excretion in humans.

1 reference

12 December 2020

Treating to target: a strategy to cure gout

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.124

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference